Shopping Cart
Remove All
Your shopping cart is currently empty
PARP/PI3K-IN-1 is a novel dual poly (ADP-ribose) polymerase (PARP) and phosphatidylinositol 3-kinase (PI3K) dual inhibitor with anticancer, antitumour and antiproliferative activities for the study of breast, pancreatic and lung cancers.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $98 | In Stock | In Stock | |
| 5 mg | $255 | In Stock | In Stock | |
| 10 mg | $396 | In Stock | In Stock | |
| 25 mg | $689 | In Stock | In Stock | |
| 50 mg | $1,070 | In Stock | In Stock | |
| 100 mg | $1,450 | - | In Stock |
| Description | PARP/PI3K-IN-1 is a novel dual poly (ADP-ribose) polymerase (PARP) and phosphatidylinositol 3-kinase (PI3K) dual inhibitor with anticancer, antitumour and antiproliferative activities for the study of breast, pancreatic and lung cancers. |
| Targets&IC50 | PI3Kγ:6.08 (pIC50), PI3Kδ:8.13 (pIC50), PARP1:8.22 (pIC50), PI3Kβ:6.54 (pIC50), PI3Kα:8.25 (pIC50), PARP2:8.44 (pIC50) |
| In vitro | PARP/PI3K-IN-1 (1 μM; 72 h) decreased the levels of self-phosphorylation of AKT and S6, while increasing the phosphorylation levels of ERK following treatment, indicating the inhibition of the PI3K pathway and activation of the ERK pathway by PARP/PI3K-IN-1, resulting in significantly increased apoptosis.[1]. In BRCA-deficient cells, PARP/PI3K-IN-1 not only exhibits significant inhibitory activity against HCC1937 and HCT116, but also demonstrates anti-proliferative activity against MDA-MB-231 and MDA-MB-468 [1]. |
| In vivo | PARP/PI3K-IN-1 (IP; 50 mg/kg; treatment for 34 days) significantly inhibits tumor growth[1]. |
| Molecular Weight | 660.62 |
| Formula | C33H28F4N8O3 |
| Cas No. | 2337386-47-5 |
| Smiles | O=C1NN=C(C=2C=CC=CC12)CC3=CC=C(F)C(=C3)C(=O)N4CC5=NC(=NC(=C5CC4)N6CCOCC6)C7=CN=C(N)C=C7C(F)(F)F |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (121.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.